Recurrent gene fusions in prostate cancer
First Claim
Patent Images
1. A method for detecting a solute carrier family 45, member 3:
- ETS-related-gene (SLC45A3;
ERG) gene fusion in a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof, the method comprising;
(a) contacting a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof with a detectably labeled probe specific for a SLC45A3;
ERG gene fusion; and
(b) detecting the SLC45A3;
ERG gene fusion by detecting a hybridized structure comprising;
i) a nucleic acid comprising a SLC45A3;
ERG gene fusion having a 5′
portion joined at a fusion junction to a 3′
portion, said 5′
portion of the gene fusion comprising 8 consecutive nucleotides from chromosome 1 at locus 1q32 and said 3′
portion comprising 8 consecutive nucleotides from chromosome 21 at locus 21q22; and
ii) said detectably labeled probe specifically hybridized to said nucleic acid and spanning said fusion junction.
2 Assignments
0 Petitions
Accused Products
Abstract
Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
88 Citations
23 Claims
-
1. A method for detecting a solute carrier family 45, member 3:
- ETS-related-gene (SLC45A3;
ERG) gene fusion in a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof, the method comprising;(a) contacting a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof with a detectably labeled probe specific for a SLC45A3;
ERG gene fusion; and(b) detecting the SLC45A3;
ERG gene fusion by detecting a hybridized structure comprising;i) a nucleic acid comprising a SLC45A3;
ERG gene fusion having a 5′
portion joined at a fusion junction to a 3′
portion, said 5′
portion of the gene fusion comprising 8 consecutive nucleotides from chromosome 1 at locus 1q32 and said 3′
portion comprising 8 consecutive nucleotides from chromosome 21 at locus 21q22; andii) said detectably labeled probe specifically hybridized to said nucleic acid and spanning said fusion junction. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- ETS-related-gene (SLC45A3;
-
9. A method for detecting a solute carrier family 45, member 3:
- ETS-related-gene (SLC45A3;
ERG) gene fusion in a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof, the method comprising;(a) contacting a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof with a first detectably labeled probe and a second detectably labeled probe; and (b) detecting the SLC45A3;
ERG gene fusion by detecting a hybridized structure comprising;i) a nucleic acid comprising a SLC45A3;
ERG gene fusion, said SLC45A3;
ERG gene fusion having a 5′
portion fused to a 3′
portion, said 5′
portion of the gene fusion comprising 8 consecutive nucleotides from chromosome 1 at locus 1q32 and said 3′
portion comprising 8 consecutive nucleotides from chromosome 21 at locus 21q22;ii) said first detectably labeled probe specifically hybridized to said 5′
portion of the SLC45A3;
ERG gene fusion; andii) said second detectably labeled probe specifically hybridized to said 3′
portion of the SLC45A3;
ERG gene fusion. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16)
- ETS-related-gene (SLC45A3;
-
17. A method for detecting a solute carrier family 45, member 3:
- ETS-related-gene (SLC45A3;
ERG) gene fusion in a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof, the method comprising;(a) contacting a human biological sample comprising prostate tissue, prostate cells, prostate secretions, or fractions thereof with a first oligonucleotide primer and a second oligonucleotide primer; (b) hybridizing the first and second oligonucleotide primers to a nucleic acid comprising a SLC45A3;
ERG gene fusion, said SLC45A3;
ERG gene fusion having a 5′
portion joined at a fusion junction to a 3′
portion, said 5′
portion of the gene fusion comprising 8 consecutive nucleotides from chromosome 1 at locus 1q32 and said 3′
portion comprising 8 consecutive nucleotides from chromosome 21 at locus 21q22;(c) amplifying a portion of the nucleic acid comprising said SLC45A3;
ERG gene fusion using a nucleic acid amplification reaction to produce a SLC45A3;
ERG gene fusion nucleic acid amplification product comprising said fusion junction; and(d) detecting the SLC45A3;
ERG gene fusion by detecting the SLC45A3;
ERG gene fusion nucleic acid amplification product comprising said fusion junction,wherein the first oligonucleotide primer is complementary to the 5′
portion of the SLC45A3;
ERG gene fusion and the second oligonucleotide primer is complementary to the 3′
portion of the SLC45A3;
ERG gene fusion.- View Dependent Claims (18, 19, 20, 21, 22, 23)
- ETS-related-gene (SLC45A3;
Specification